Sobi and Selecta announce strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout
· Strategic licensing agreement for SEL-212, a unique phase 3-ready therapy powered by Selecta’s breakthrough immune tolerance platform, ImmTOR™, with the potential to fulfil a significant unmet need for the treatment of chronic refractory gout · Builds on Sobi’s strategy and expertise to develop and commercialise novel therapies within the area of immunology · Sobi to take on development, regulatory and commercial activities in all markets outside China while Selecta to run the phase 3 study on behalf of Sobi · Selecta to receive from Sobi initial payments of USD 100 million,